Overview Dividends

(NTRA) Natera - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6323071042

Panorama, Horizon, Vistara, Spectrum, Signatera

Biotechnology
Market Cap in USD: 32,220m

IPO / Inception: 2015-07-02
Return 12m vs S&P 500: 24.8%

EPS (Earnings per Share)

EPS CAGR: 79.87%
EPS Trend: 84.4%

Last SUE: -1.52
Qual. Beats: 0

Revenue

Rev. CAGR: 38.83%
Rev. Trend: 99.3%

Last SUE: 3.26
Qual. Beats: 11

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	43.5%
Value at Risk 5%th	66.4%
Relative Tail Risk	-7.23%

Reward TTM
Sharpe Ratio	1.09
Alpha	21.87
CAGR/Max DD	1.96

Character TTM
Hurst Exponent	0.558
Beta	1.208
Beta Downside	1.132

Drawdowns 3y
Max DD	39.94%
Mean DD	8.18%
Median DD	5.52%

Description: NTRA Natera December 19, 2025

Natera, Inc. (NASDAQ: NTRA) is a global molecular diagnostics firm that commercializes a portfolio of DNA-based tests spanning reproductive health, oncology, organ transplantation, and rare-disease screening. Core offerings include Panorama (non-invasive prenatal testing), Signatera (personalized circulating tumor DNA monitoring), and a suite of carrier-screening, pre-implantation genetic testing, and transplant-rejection assays, delivered through a mix of direct sales and partner laboratories. Strategic collaborations with BGI Genomics and Foundation Medicine expand its next-generation sequencing (NGS) capabilities and market reach.

Key performance indicators from the most recent fiscal year show revenue of roughly $1.0 billion, up about 20 % year-over-year, driven primarily by strong growth in the Panorama and Signatera lines. The company maintains an industry-leading gross margin near 80 % and reported cash and short-term investments of approximately $400 million, providing runway for R&D and potential acquisitions. Sector-wide, the NIPT market is projected to expand at a CAGR of ~10 % through 2029, while oncology-focused liquid biopsy adoption is accelerating as payers broaden reimbursement for personalized cancer monitoring.

For a deeper quantitative assessment of NTRA’s valuation metrics, the ValueRay platform offers a concise, data-driven dashboard worth reviewing.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (-309.2m TTM) > 0 and > 6% of Revenue (6% = 127.0m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA 7.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 47.49% (prev 66.66%; Δ -19.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.11 (>3.0%) and CFO 194.3m > Net Income -309.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (137.2m) change vs 12m ago 10.84% (target <= -2.0% for YES)

Gross Margin 63.70% (prev 57.66%; Δ 6.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 124.1% (prev 96.29%; Δ 27.76pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -69.90 (EBITDA TTM -268.8m / Interest Expense TTM 4.37m) >= 6 (WARN >= 3)

Altman Z'' -7.84

(A) 0.55 = (Total Current Assets 1.45b - Total Current Liabilities 442.0m) / Total Assets 1.82b

(B) -1.55 = Retained Earnings (Balance) -2.82b / Total Assets 1.82b

warn (B) unusual magnitude: -1.55 — check mapping/units

(D) -4.96 = Book Value of Equity -2.82b / Total Liabilities 569.3m

Total Rating: -7.84 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 47.90

1. Piotroski 4.50pt

2. FCF Yield 0.30%

3. FCF Margin 4.42%

4. Debt/Equity 0.15

5. Debt/Ebitda 3.19

6. ROIC - WACC (= -33.72)%

7. RoE -25.07%

8. Rev. Trend 99.30%

9. EPS Trend 84.39%

What is the price of NTRA shares?

As of December 20, 2025, the stock is trading at USD 231.96 with a total of 2,218,171 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +6.23%, over three months by +28.08% and over the past year by +46.73%.

Is NTRA a buy, sell or hold?

Natera has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NTRA.

Strong Buy: 12
Buy: 8
Hold: 0
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the NTRA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	238.6	2.9%
Analysts Target Price	238.6	2.9%
ValueRay Target Price	314.6	35.6%

NTRA Fundamental Data Overview December 13, 2025

Market Cap USD = 32.22b (32.22b USD * 1.0 USD.USD)
P/S = 15.2218
P/B = 25.9624
Beta = 1.626
Revenue TTM = 2.12b USD
EBIT TTM = -305.5m USD
EBITDA TTM = -268.8m USD
Long Term Debt = 118.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 80.3m USD (from shortTermDebt, last quarter)
Debt = 184.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -856.7m USD (from netDebt column, last quarter)
Enterprise Value = 31.36b USD (32.22b + Debt 184.7m - CCE 1.04b)
Interest Coverage Ratio = -69.90 (Ebit TTM -305.5m / Interest Expense TTM 4.37m)
FCF Yield = 0.30% (FCF TTM 93.6m / Enterprise Value 31.36b)
FCF Margin = 4.42% (FCF TTM 93.6m / Revenue TTM 2.12b)
Net Margin = -14.61% (Net Income TTM -309.2m / Revenue TTM 2.12b)
Gross Margin = 63.70% ((Revenue TTM 2.12b - Cost of Revenue TTM 768.4m) / Revenue TTM)
Gross Margin QoQ = 64.91% (prev 63.50%)
Tobins Q-Ratio = 17.22 (Enterprise Value 31.36b / Total Assets 1.82b)
Interest Expense / Debt = 0.57% (Interest Expense 1.04m / Debt 184.7m)
Taxrate = -0.24% (negative due to tax credits) (207.0k / -87.3m)
NOPAT = -306.2m (EBIT -305.5m * (1 - -0.24%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.27 (Total Current Assets 1.45b / Total Current Liabilities 442.0m)
Debt / Equity = 0.15 (Debt 184.7m / totalStockholderEquity, last quarter 1.25b)
Debt / EBITDA = 3.19 (negative EBITDA) (Net Debt -856.7m / EBITDA -268.8m)
Debt / FCF = -9.16 (Net Debt -856.7m / FCF TTM 93.6m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.97% (Net Income -309.2m / Total Assets 1.82b)
RoE = -25.07% (Net Income TTM -309.2m / Total Stockholder Equity 1.23b)
RoCE = -22.60% (EBIT -305.5m / Capital Employed (Equity 1.23b + L.T.Debt 118.4m))
RoIC = -23.31% (negative operating profit) (NOPAT -306.2m / Invested Capital 1.31b)
WACC = 10.41% (E(32.22b)/V(32.40b) * Re(10.47%) + D(184.7m)/V(32.40b) * Rd(0.57%) * (1-Tc(-0.00)))
Discount Rate = 10.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.23%
[DCF Debug] Terminal Value 60.36% ; FCFE base≈93.6m ; Y1≈61.4m ; Y5≈28.1m
Fair Price DCF = 2.80 (DCF Value 390.1m / Shares Outstanding 139.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 84.39 | EPS CAGR: 79.87% | SUE: -1.52 | # QB: 0
Revenue Correlation: 99.30 | Revenue CAGR: 38.83% | SUE: 3.26 | # QB: 11
EPS next Quarter (2026-03-31): EPS=-0.59 | Chg30d=-0.265 | Revisions Net=-7 | Analysts=11
EPS next Year (2026-12-31): EPS=-1.95 | Chg30d=-0.364 | Revisions Net=-13 | Growth EPS=+20.3% | Growth Revenue=+17.0%

Additional Sources for NTRA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle